|
India’s Biosimilar Guidelines Promise Less Clinical Requirements
Like its FDA counterparts, Indian regulators promise fewer clinical trials for biosimilars makers who can prove their product closely matches its reference product, according to new guidelines.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives